Unmodified performance in runners following anabolic steroid administration

Area of Science:

• Sports Medicine
• Endocrinology
• Exercise Physiology

Background:

• Anabolic-androgenic steroids (AAS) are often misused by athletes seeking performance enhancement.
• Stanozolol is a synthetic AAS with a history of use in athletic contexts.
• The effects of low-dose stanozolol on specific physiological markers of athletic performance require further elucidation.

Purpose of the Study:

• To investigate the impact of a low daily dose of stanozolol on key physiological performance indicators in elite runners.
• To assess the hormonal responses, specifically testosterone (T), interstitial cell-stimulating hormone (ICSH), and follicle-stimulating hormone (FSH), to stanozolol administration.
• To determine if stanozolol, at a dose affecting hormonal levels, can enhance athletic performance.

Main Methods:

• A 6-week experimental trial involving ten well-trained runners.
• Administration of a low dose of stanozolol (10 mg/day).
• Measurement of anaerobic threshold (AT), maximal velocity (Vmax), competition running times, and serum hormone levels (T, ICSH, FSH) at baseline, during, and post-treatment.

Main Results:

• No significant improvements were observed in anaerobic threshold (AT) or maximal velocity (Vmax).
• Competition running times did not improve during the 6-week experimental period.
• Serum testosterone (T) levels showed a marked decrease, while ICSH and FSH levels remained statistically unchanged.

Conclusions:

• Low-dose stanozolol treatment, even when sufficient to suppress testicular function (indicated by decreased T), does not enhance athletic performance in well-trained runners.
• The study suggests that the potential hormonal disruptions caused by stanozolol at this dose outweigh any theoretical performance benefits.
• Findings indicate stanozolol is ineffective for improving running performance markers like AT and Vmax.